HKU and BNU astrophysicists use wave simulations to open a new window on dark matter
Peer-Reviewed Publication
Updates every hour. Last Updated: 24-Oct-2026 19:16 ET (24-Oct-2026 23:16 GMT/UTC)
The Bezos Earth Fund is granting $18 million for ROOTS, a three-year Salk project to test deeper-rooted, more resilient crops that can store more carbon in soil. The project builds on six years of work through Salk’s Harnessing Plants Initiative, which has identified 347 gene candidates and advanced 37 projects across genes and crops. The grant brings the Bezos Earth Fund’s total support for Salk to $48 million.
A team led by University at Buffalo physicists has found a mathematical solution that shows how a frustrated quantum magnet can transition from ultraslow behavior to ultrafast, highly entangled behavior resembling that of a black hole.
Insilico Medicine will present the first clinical findings for ISM6331, its AI-designed pan-TEAD inhibitor, during a Rapid Oral session at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid. The presentation will report initial safety, pharmacokinetic and antitumor findings from a global, multicenter Phase I study in patients with mesothelioma and other advanced solid tumors.
Designed with support from Insilico’s generative chemistry platform Chemistry42, ISM6331 is an investigational oral small molecule that inhibits all four TEAD family transcription factors, disrupting tumor-promoting signals associated with Hippo pathway dysregulation. The program has received U.S. FDA Orphan Drug Designation and Fast Track Designation for mesothelioma.
ISM6331 reflects Insilico’s strategy of using AI to develop precisely designed medicines against difficult-to-treat, age-associated diseases. The presentation will take place Sunday, October 25, from 8:30–10:00 a.m. CEST in the Cordoba Auditorium – Hall 4.